Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:TMCI

Treace Medical Concepts Q3 2026 Earnings Date & Estimates

Treace Medical Concepts logo
$3.95 +0.07 (+1.80%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$3.94 -0.01 (-0.13%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Treace Medical Concepts is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Treace Medical Concepts in Q3 2026

Treace Medical Concepts is expected to post earnings of -$0.26 per share on revenue of $47.71 million. In the same quarter a year earlier Treace Medical Concepts reported -$0.26 per share on revenue of $50.21 million. Treace Medical Concepts last reported on August 7, 2026, posting -$0.24 per share and beating the -$0.2980 consensus estimate. Treace Medical Concepts has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.26
Expected Revenue
$47.71 million
Prior-Year EPS
-$0.26
Prior-Year Revenue
$50.21 million
Expected Revenue Growth
-5.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.24 (Beat by +$0.0580)
Last Quarter Revenue
$45.38 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Treace Medical Concepts Q3 2026 Earnings FAQ

Treace Medical Concepts (NASDAQ:TMCI) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Treace Medical Concepts' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Treace Medical Concepts to post earnings of -$0.26 per share for Q3 2026.

The consensus revenue estimate for Treace Medical Concepts is $47.71 million for Q3 2026.

Treace Medical Concepts Earnings Headlines

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068145
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
September 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-treace-medical-concepts-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302890728.html
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
October 10 at 1:00 AM  |  Porter & Company (Ad)
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
September 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/treace-medical-tmci-reports-five-year-bunion-results-can-evidence-drive-adoption-1840580/
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure
September 18, 2026  |  marketscreener.comM
Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...
September 18, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69614222-treace-medical-concepts-inc-treace-announces-results-of-three-clinical-studies-including-the-milestone-5-year-align3d-study-demonstrating-sustained-399.htm
See More Treace Medical Concepts Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Treace Medical Concepts? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Treace Medical Concepts and other key companies, straight to your email.

About Treace Medical Concepts

Treace Medical Concepts (NASDAQ:TMCI) is a medical technology company focused on advancing surgical treatment for bunions and other deformities of the big toe and forefoot. The company develops and commercializes medical devices, surgical instruments and procedure-based solutions designed to address the underlying structural causes of bunion deformities.

Its flagship offering is the Lapiplasty 3D Bunion Correction System, which is intended to correct bunions in three dimensions and stabilize the affected joint. Treace also offers related products and technologies, including the Adductoplasty system for addressing associated metatarsal deformities and specialized plates, implants and instruments used in bunion-correction procedures.

Founded in 2013, Treace markets its products primarily to orthopedic and podiatric surgeons and supports adoption through physician education, surgical training and procedural resources. The company is headquartered in Ponte Vedra Beach, Florida, and was founded by John T. Treace, who has served as its chairman and chief executive officer. Its products are primarily used in the United States, with the company working to expand access to its surgical solutions in additional markets.

View Treace Medical Concepts Profile
Earnings Tools